The companies also announced that Xoma has successfully completed the Human Engineering of AV-299. This agreement further strengthens the collaboration between the companies that began with the humanization of AV-299.
Under the supply agreement, Xoma will create AV-299 production cell lines, and conduct process and assay development, as well as cGMP manufacturing activities in support of Aveo’s initial drug filing and early clinical trials.
In April 2006, Xoma and Aveo announced an agreement under which Xoma would use its HE technology to humanize AV-299. XOMA created four Human Engineered versions of the original AV-299, all of which met design goals and were delivered ahead of schedule.
For work conducted and licenses granted, Xoma received an up-front license fee and is eligible for development milestones and royalty payments on sales of AV-299. Aveo retains all development and commercialization rights to AV-299.
“We expect this to be the first of many HE technology agreements that evolve into broader relationships and allow us to leverage Xoma’s innovations, expertise and antibody development infrastructure,” said Jack Castello, president and CEO of Xoma.